NNMX Stock Analysis
NN
Uncovered
Nanomix Corp is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Nanomix Corp. focuses on the development of a mobile point-of-care diagnostics system that can be used in performing a wide range of in vitro diagnostic tests in many environments. The company is headquartered in Lawrence, Massachusetts. The company went IPO on 2012-02-29. The firm operates through its Nanomix eLab System platform and assays that provide quantitative information for use in settings where time is critical to clinical decision-making and improved patient care. The platform is designed to provide rapid test results in a handheld device at the first point of patient contact in locations that range from emergency departments to long term and assisted care facilities, to urgent care and emergency medical response settings. Its platform is performed in a range of in vitro diagnostic assays, such as electrochemical immunoassay and enzymatic assays. The company utilizes a proprietary nano-biosensor with multiple detection electrodes to generate multiple electrochemical assay results from a single patient sample. The Nanomix eLab COVID-19 Rapid Panel is an electrochemical immunoassay test for qualitative detection of SARS-CoV-2 in human venous whole blood and plasma.